The KOL event and upcoming ELAINE-3 data catalyst in 2H27 create a clear binary near-term value inflection. Traders should monitor for enrollment completion confirmation in 4Q26 and prepare for potential stock movement on 2H27 data readout.
Price Chart
Executive Summary
LeonaBio announced a virtual Key Opinion Leader event featuring two prominent breast cancer experts to discuss the potential of lasofoxifene in metastatic breast cancer, ahead of expected Phase 3 ELAINE-3 trial data in 2H27. The company highlighted clinical data from earlier trials showing improved progression-free survival and response rates in ESR1-mutated patients.
Key Facts
- LeonaBio is hosting a KOL event on April 29, 2026, to discuss lasofoxifene's potential in ER+, HER2-, ESR1-mutated metastatic breast cancer.
- ELAINE-3 Phase 3 trial enrollment is expected to complete in 4Q26, with data readout anticipated in 2H27.
- Phase 2 data showed lasofoxifene improved median progression-free survival (5.6 vs 3.7 months) and objective response rates (13.3% vs 2.9%) versus fulvestrant in ELAINE-1.
- In ELAINE-2, lasofoxifene plus abemaciclib achieved a 56% objective response rate and 13-month median PFS in heavily pretreated patients.
Financial Impact
Potential blockbuster drug in a $41.7B growing market by 2030; no direct financials reported but clinical momentum is significant.
Risk Factors
- Clinical trial delays or failure to meet endpoints in ELAINE-3 could derail development plans.
- Regulatory uncertainty and potential FDA objections to trial design or safety profile.
- Competition from existing and emerging therapies in the metastatic breast cancer space.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3280370 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | SC 13D/A | $4.79 | awaiting T+60 | — | $4.76 (−0.63%) |
May 11, 2026 24w ago | DEFA14A | $10.17 $7.81 | ▼ −23.21% | ▼ −27.59% | $4.76 (−53.20%) |
May 7, 2026 24w ago | 3 | $10.04 $7.66 | ▼ −23.71% | ▼ −28.54% | $4.76 (−52.59%) |
Apr 23, 2026 26w ago | Press Release | $8.33 $7.98 | ▼ −4.20% | ▼ −9.28% | $4.76 (−42.86%) |
Mar 26, 2026 30w ago | Press Release | $8.97 $8.41 | ▼ −6.24% | ▼ −22.31% | $4.76 (−46.93%) |
Mar 4, 2026 33w ago | Insider Cluster | $5.98 $9.64 | ▲ +61.20% | ▲ +51.12% | $4.76 (−20.40%) |
Mar 4, 2026 33w ago | Insider Cluster | $5.98 $9.64 | ▲ +61.20% | ▲ +51.12% | $4.76 (−20.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers